Krystal Biotech
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Krystal Biotech generated cash of -$88,804,000, which is more than the previous year. Cash used in financing activities reached the amount of $202,750,000 last year. Net change in cash is therefore $196,428,000.
Cash Flow
| 2016 | -1.31M | -15K | 3.24M |
|---|---|---|---|
| 2017 | -3.89M | -210K | 51.76M |
| 2018 | -9.44M | -10.32M | 73.84M |
| 2019 | -18.71M | -4.96M | 107.52M |
| 2020 | -26.08M | -11.18M | 118.01M |
| 2021 | -47.93M | -226.77M | 347.68M |
| 2022 | -100.56M | -114.08M | 35.34M |
| 2023 | -88.80M | 82.63M | 202.75M |
KRYS Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 161.9M | 341.24M | 268.26M | 187.51M | 103.67M | 49.59M | 1.92M | 0 |
Operating activities | ||||||||
Net income | 10.93M | -139.97M | -69.57M | -32.16M | -19.08M | -10.88M | -7.92M | -1.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 5.00M | 4.05M | 2.76M | 1.85M | 748K | 141K | 23K | 2K |
Stock-based compensation expense | 39.93M | 33.23M | 15.31M | 3.27M | 1.23M | 0 | 246K | 33K |
| Deferred income tax benefit | 39.93M | 33.23M | 15.31M | 3.27M | 1.23M | 0 | 246K | 33K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -42.04M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | -4.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -101K | -1.25M | 712K | 783K | -199K | 112K | 133K | 42K |
Cash generated by operating activities | -88.80M | -100.56M | -47.93M | -26.08M | -18.71M | -9.44M | -3.89M | -1.31M |
Investing activities | ||||||||
Purchases Of Investments | -508.77M | -318.78M | -190.46M | -3.20M | -9.07M | -8.08M | 0 | 0 |
Investments In Property Plant And Equipment | -11.79M | -52.97M | -68.33M | -14.84M | -6.39M | -2.23M | -210K | -15K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 82.63M | -114.08M | -226.77M | -11.18M | -4.96M | -10.32M | -210K | -15K |
Financing activities | ||||||||
Common Stock Issued | 203.49M | 35.99M | 355.64M | 118.01M | 107.52M | 73.84M | 42.46M | 100K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 2.29M | 0 |
Cash used in financing activities | 202.75M | 35.34M | 347.68M | 118.01M | 107.52M | 73.84M | 51.76M | 3.24M |
Net Change In Cash | 196.42M | -179.34M | 72.97M | 80.75M | 83.84M | 54.07M | 47.66M | 1.92M |
Cash at end of period | 358.32M | 161.9M | 341.24M | 268.26M | 187.51M | 103.67M | 49.59M | 1.92M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |